Phaseline

Companies › Yuhan

Yuhan: clinical trials, targets and expected readouts

9 active drug programs in 10 registered trials: 6 Phase 1, 2 Phase 4, 1 Phase 2, 1 Phase 3; Other, Oncology, Cardiovascular, Metabolic and endocrine; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Telmisartan
Type-1 angiotensin II receptor antagonist
AGTR1Phase 4Essential Hypertension–
NTCB02-1–Phase 3Parenteral Nutrition–
Lesigercept
High-affinity IgE receptor (FcεRI) antagonist
FCER1APhase 2Allergic DiseasesJun 2027
YHP2508B–Phase 1Healthy Subjects (HS)Jan 2027
YHP2508A–Phase 1Healthy Subjects (HS)Feb 2027
YH35995–Phase 1Healthy ParticipantsMar 2027
YH32364
EGFR-targeting agent
EGFRPhase 1EGFR OverexpressionJun 2027
YH42946
Dual EGFR exon 20 insertion and HER2 inhibitor
EGFR, ERBB2Phase 1NSCLC (Non-small Cell Lung Cancer)Mar 2028
YH32367
HER2-targeted therapy
ERBB2Phase 1HER2-Positive Solid TumorMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06625957NTCB02-1Phase 3Parenteral NutritionOtherJul 2025
NCT06041529TelmisartanPhase 4Essential HypertensionCardiovascularFeb 2026
NCT06041529TelmisartanPhase 4Essential HypertensionCardiovascularFeb 2026
NCT07912840YHP2508BPhase 1Healthy Subjects (HS)OtherJan 2027
NCT07912827YHP2508APhase 1Healthy Subjects (HS)OtherFeb 2027
NCT06517914YH35995Phase 1Healthy ParticipantsMetabolic and endocrineMar 2027
NCT06975410YH32364Phase 1EGFR OverexpressionOncologyJun 2027
NCT07415551LesigerceptPhase 2Allergic DiseasesImmunologyJun 2027
NCT06616766YH42946Phase 1NSCLC (Non-small Cell Lung Cancer)OncologyMar 2028
NCT05523947YH32367Phase 1HER2-Positive Solid TumorOncologyMar 2028

Targets

EGFR (2) ERBB2 (2) AGTR1 (1) FCER1A (1)

Companies with the same targets

Beijing Biotech AstraZeneca Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Jiangsu HengRui Medicine Roche Allist Pharmaceuticals Sichuan Baili Pharmaceutical Dizal Pharmaceuticals

Companies built like this

Jiangsu Hansoh Pharmaceutical HC Biopharma Sunshine Lake Pharma Abbisko Therapeutics Haisco Pharmaceutical Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.